{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Talzenna"},{"type":"Synonym","name":"PARP inhibitor BMN-673"},{"type":"CodeName","name":"BMN-673"},{"type":"CodeName","name":"BMN 673"},{"type":"CASRegistryName","name":"1373431-65-2"}],"definition":{"html":"The tosylate salt form of talazoparib, an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","text":"The tosylate salt form of talazoparib, an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/talazoparibtosylate","text":"Talazoparib Tosylate"},"nciConceptId":"C152494","nciConceptName":"Talazoparib Tosylate","termId":694964,"name":"talazoparib tosylate","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"talazoparib-tosylate"}],"links":null}